
BioCryst (BCRX) | Stock Overview & Key Data
BioCryst Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $37.25 on March 6, 2000
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
---|---|---|---|---|---|---|---|---|---|
BioCryst BCRX | 1.55B Small-cap | -7.02% | -14.29% | -19.86% | 3.39% | -10.34% | -5.52% | -48.12% | 82.34% |
Zoetis ZTS | 65.09B Large-cap | 2.03% | -3.94% | -8.02% | -8.26% | -9.96% | -22.95% | -0.64% | -11.49% |
Haleon Plc - ADR HLN | 41.44B Large-cap | -0.57% | -9.75% | -13.40% | -5.18% | -6.89% | -12.54% | 45.53% | 18.62% |
BGM BGM | 1.91B Small-cap | 3.02% | 35.06% | -1.00% | -6.78% | 10.74% | 37.88% | 58.40% | -77.37% |
Tilray Brands TLRY | 1.81B Small-cap | -14.59% | 41.07% | 216.00% | 172.41% | 8.22% | -3.07% | -49.68% | -71.58% |
Harrow HROW | 1.68B Small-cap | -12.89% | 6.01% | 34.44% | 82.59% | 15.32% | -16.86% | 249.88% | 621.92% |
Ownership & Short Interest
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BCRX's 52-week high and low?
- In the last 52 weeks, BioCryst reached a high of $11.31 (on June 4, 2025) and a low of $6.02 (on April 10, 2025).
- What is the market cap and P/E ratio for BCRX?
- Curious about BioCryst's size and valuation? Its market capitalization stands at 1.55B. When it comes to valuation, the P/E ratio (trailing twelve months) is -16.63, and the forward P/E (looking ahead) is -178.75.
- Does BCRX pay dividends? If so, what's the yield?
- As for dividends, BioCryst isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are BioCryst's main competitors or similar companies to consider before investing?
When looking at BioCryst, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS65.09B Healthcare Drug Manufacturers - Specialty & Generic -22.95% -0.64% Haleon Plc - ADR
HLN41.44B Healthcare Drug Manufacturers - Specialty & Generic -12.54% 45.53% BGM
BGM1.91B Healthcare Drug Manufacturers - Specialty & Generic 37.88% 58.40% Tilray Brands
TLRY1.81B Healthcare Drug Manufacturers - Specialty & Generic -3.07% -49.68% Harrow
HROW1.68B Healthcare Drug Manufacturers - Specialty & Generic -16.86% 249.88% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for BioCryst Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of BioCryst's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 18.68%, the Debt to Equity ratio from the most recent quarter is -1.75, and its Gross Profit Margin stands at 98.29%.
- What is the recent revenue and earnings growth for BCRX?
- Looking at BioCryst's growth, its revenue over the trailing twelve months (TTM) was $558M. Compared to the same quarter last year (YoY), quarterly revenue grew by 49.40%, and quarterly earnings saw a YoY growth of 49.41%.
- How much of BCRX stock is held by insiders and institutions?
- Wondering who owns BioCryst stock? Company insiders (like executives and directors) hold about 1.19% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 99.39%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.